fbpx
 

ENZYME BLOGAnalyzing the latest developments in regulatory, compliance, and quality

MedTech Makers Can Get Devices to US Market Faster, Hasten Innovation By Drafting PCCP Change Plans, Industry Experts Say

By Shawn M. Schmitt Communications Specialist, Enzyme A Predetermined Change Control Plan (PCCP) submitted to and approved by the US Food and Drug Administration (FDA) as part of the medical device review process can give some manufacturers a leg up by shaving months off of the time it can take for a product to come...

Ex-FDA Reviewer On PCCP Policy: ‘Child of Pre-Cert’ Evolves Into ‘No-Surprise’ Tool for Makers of Changing MedTech

By Shawn M. Schmitt Communications Specialist, Enzyme A former US Food and Drug Administration official who contributed to the FDA’s draft guidance shaping the agency’s thinking on Predetermined Change Control Plans for medical devices is bullish on PCCP’s ability to get updated products to patients faster – and believes it’s a win-win for manufacturers and...